Featuring

18th Orphan Drugs & Rare Diseases Global Congress 2022 Americas - East Coast

Addressing Scientific Challenges to Advance New Treatments for Rare Diseases

Days
Hours
Minutes
Seconds

21st September 2022 - Pre-Conference Workshops
22nd - 23rd September 2022 - 2 Days Conference

Venue

Hilton Boston Logan Airport

Address

One Hotel Dr, Boston, MA 02128, United

Phone

617-568-6700

18th Orphan Drugs & Rare Diseases Global Congress 2022 - US Boston

Orphan Drugs & Rare Diseases

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases Global Congress 2022 Americas. It’s the 18th in the series of our Flagship tri-annual Orphan Drugs & Rare Diseases event. This congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

The COVID-19 Pandemic has impacted the lives of just about everyone, patients receiving continuous treatment and care included. The Rare Disease community is already experiencing considerable challenges in achieving early and detailed diagnosis and having access to care and life-saving treatment, to chronic, highly complex, progressive and severely disabling nature of their diseases, which generate specific care needs. Undoubtedly, during this crisis, the rare diseases community is experiencing unprecedented overall disruption even more….

From a patient advocacy organization perspective, was a very informative meeting. Learned a lot from presentations and networking that will inform how we can add value to the advocacy-patient-drug developer dialogue.

aftd
Dr. Nadine Tutton

Scientific Director, Research, Association for Frontotemporal Degeneration

I was very impressed with the format, the content was interesting and well done. I felt I learned a lot and was glad to be able to attend.

pharmolam
Senior Director

Business Development at Pharm-Olam, LLC

Introducing

2022 CONFERENCE FORMAT

The two-day Congress will provide an interactive, cutting edge and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.

Orphan Drugs & Rare Diseases 2022 Americas

Sponsors

Gold Sponsor

Gold Sponsor

Gold Sponsor

Gold Sponsor

Associate Sponsor

Associate Sponsor

Associate Sponsor

Lead Exhibitor

Scroll to Top

Dear Colleagues,

Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases
Global Congress 2021 Americas. It’s the 16th in the series of our Flagship tri-annual Orphan
Drugs & Rare Diseases event. This congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

The COVID-19 Pandemic has added urgency and profoundly impacted the lives of rare disease patients because they are amongst the most vulnerable to Covid-19. The community is already experiencing considerable challenges in achieving early and detailed diagnosis and having access to care and life-saving treatment, to chronic, highly complex, progressive, and severely disabling nature of their diseases, which generate specific care needs. Undoubtedly, during this crisis, the rare diseases community is experiencing unprecedented overall disruption even more…

According to reports (Fortune Business Insights), the global orphan drugs market size was
valued at USD 151 billion in 2019 and is projected to reach 340.84 billion by 2027. The oncology therapy area possesses a substantially higher share in the global market as new cancer-related disease emerges and series of FDA approvals will result in increased commercialisation of these drugs. The growing demand for immunomodulators will also contribute to the orphan drugs market growth. Increasing R&D initiatives and investments by prominent players and patient advocacy involvement have resulted in major pharmaceutical breakthroughs, and the development of blockbuster drugs for the treatment of several rare diseases will create opportunities and contribute exponentially to the overall market growth.

However, the coronavirus pandemic is expected to negatively impact the global market. Another critical factor restricting the orphan drugs market is the high cost associated with this drug which can significantly limit the widespread adoption of this product, especially in emerging countries.

The two-day Congress aims to bring together stakeholders to discuss strategies and best
practices, innovations, technologies and concepts that can promote rare diseases product
development in an interactive, thought-provoking and uplifting manner, by way of a keynote
presentation, plenary sessions, panel discussions, roundtables and stream sessions.

We look forward to welcoming you to the congress!

Jocelyn Raguindin
Jocelyn Raguindin

Jocelyn is Conference Director at Paradigm Global Events (PGE). She has over 15+ years experience in organizing pharma-industry conferences and has been at the helm of every PGE conference since 2013. Jocelyn is based in London, UK.

Gain Latest Insights on:

Who Should Attend

Rogerio Vivaldi,

M.D., M.B.A., President and Chief Executive Officer, Sigilon Therapeutics Inc.

Rogerio Vivaldi Coelho, M.D., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018 and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme’s rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme’s Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi serves on the Board of Directors of Crinetics Pharmaceuticals, Inc. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro.
 

Sonal Bhatia

Chief Medical Officer, Rare Disease, Pfizer

Sonal Bhatia was recently appointed Chief Medical Officer for Rare Disease.  
Prior to this role, Sonal held the position of VP, North America Medical Affairs Lead for Rare Disease.  Sonal played a key part in the successful launch of Tafamidis, which is still ongoing worldwide for Rare Disease. She also has experience preparing the healthcare marketplace for innovative solutions for the delivery of medicines to patients, which will be critical to our future gene therapy pipeline. Sonal also previously served as Senior Medical Director & Team Lead at Pfizer, for Eliquis.

Sonal received her medical degree from Ross University School of Medicine and completed her residency in Internal Medicine at the Mount Sinai School of Medicine in New York.  Sonal holds a dual bachelor’s degree in Cell & Molecular Biology and Spanish Studies from University of Toronto, Canada.  Sonal is actively involved with AHA & AHA Go Red for Women, non-profit organizations focused on reducing disparities for access to cardiovascular health and healthy living and being catalyst for change for women’s health.  She currently serves on the Board of Directors & Executive Leadership respectively.

Sonal lives in Roosevelt Island, New York City, and loves spending time with her two children. In her spare time, she enjoys traveling, Zumba dancing, practicing yoga, and creating new cocktails. 

Christopher Dandrea

Vice President, Global Program Management, uniQure

Chris Dandrea is a 25 year veteran in the Biopharmaceutical Research, Development and Commercialization space.  His current role as uniQure’s Vice President of Global Program Management is focused on scale-up, acceleration and productivity of uniQure’s growing Research & Development Pipeline of CNS/Neuro and Rare Gene Therapy programs.  Prior to uniQure, Chris was Sanofi’s Head of Oncology Project Management tasked to build a next-generation project management organization to support rapid oncology portfolio growth.   Additional experience includes Rare Disease Program Leadership at Genzyme, Life Science Management Consulting, Medical Device Engineering and service as a US Naval Officer.  Education includes Engineering degrees from Duke University and an MBA from Carnegie Mellon University.  

Christine Von Raesfeld

Founder & CEO, People with Empathy

As Founder/CEO of People with Empathy, Christine Von Raesfeld is a leader in bringing a critically needed patient perspective to cutting-edge medical innovations. Committed to providing patients with chronic and rare diseases with the support they need, Christine works with patient advocacy organizations, industry representatives, and individual patients and their loved ones. Living with many rare and chronic diseases, she believes that the only way to ensure health equity is to leverage one’s own data. As a patient involved in Stanford’s Humanwide program, she speaks on the benefits and advantages of precision medicine, with a special interest in pharmacogenomics. 

Christine’s drive to make lives better for patients has been nationally recognized. In 2019, she spoke on stage at the Startup Health Festival as an invited guest of Sanguine Biosciences. In 2018, Christine served on the Team of Patient Advisors for PatientsLikeMe. She has been nationally recognized for her work in advocacy and when several awards including Silicon Valley Business Journal’s100 Women of Influence, 2019 and a 2020 Community Hero by Assemblyman Kansen Chu. In addition, Christine serves as a Virtual Advisor Team member for the All of Us research program, a Technical Expert Panelists for CMS and a patient advisor/consultant or multiple pharmaceuticals off branded campaigns and startup ventures.